Properties (53)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
drug
|
| gptkbp:approves |
gptkb:FDA
|
| gptkbp:availableIn |
generic version
|
| gptkbp:brand |
Jakafi
|
| gptkbp:chemicalFormula |
C17H18N4O5S
|
| gptkbp:clinicalTrials |
Phase III
treatment of psoriasis treatment of multiple sclerosis treatment of rheumatoid arthritis treatment of ulcerative colitis treatment of Crohn's disease treatment of alopecia areata treatment of atopic dermatitis treatment of graft-versus-host disease treatment of systemic lupus erythematosus treatment of systemic sclerosis treatment of vasculitis |
| gptkbp:contraindication |
severe liver impairment
active infection hypersensitivity to ruxolitinib |
| gptkbp:drugInterdiction |
metabolized by CYP3A4
strong CYP3A4 inducers strong CYP3A4 inhibitors bioavailability 100% (oral) halfLife 3.5 hours |
| gptkbp:established |
gptkb:Incyte_Corporation
|
| gptkbp:formulation |
tablet
|
| gptkbp:gestationPeriod |
Category C
|
| gptkbp:hasAwards |
unknown
|
| https://www.w3.org/2000/01/rdf-schema#label |
Ruxolitinib
|
| gptkbp:isATypeOf |
941678-49-5
|
| gptkbp:issuedBy |
oral tablet
|
| gptkbp:lastProduced |
2011
|
| gptkbp:mandates |
myelofibrosis
polycythemia_vera |
| gptkbp:marketedAs |
gptkb:Australia
gptkb:Canada gptkb:European_Union gptkb:United_States |
| gptkbp:operates_in |
L01XE10
|
| gptkbp:patentStatus |
patented
|
| gptkbp:researchAreas |
oncology
hematology immunology |
| gptkbp:route |
oral
|
| gptkbp:sideEffect |
anemia
increased risk of infections thrombocytopenia elevated liver enzymes |
| gptkbp:targets |
Janus_kinase
|
| gptkbp:triggerType |
JAK1 and JAK2 inhibitor
|
| gptkbp:usedFor |
treatment of myelofibrosis
treatment of polycythemia vera |